Equity Overview
Price & Market Data
Price: $0.545
Daily Change: -$0.0041 / 0.75%
Range: $0.545 - $0.545
Market Cap: $80,379,448
Volume: 285
Performance Metrics
1 Week: 4.49%
1 Month: 2.65%
3 Months: -47.20%
6 Months: -34.98%
1 Year: -58.08%
YTD: -15.59%
Company Details
Employees: 210
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.